Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say
This article was originally published in The Pink Sheet Daily
Executive Summary
ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.
You may also be interested in...
Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.